Kayentis deploys a record US expansion in 2025 driven by strategic partnerships; new Chief Commercial Officer (CCO) Amy Jones will further propel growth and deepen biotech, key pharma, and CRO relationships.
Grenoble, France – September 18, 2025– Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA), announces a record-breaking 40% increase in orders for the past year, with exceptional momentum in the United States. This surge is driven by strong development of leading Top Pharma accounts, and also key Biotech accounts, on both the East and West Coasts, reinforcing Kayentis’ position as a trusted partner for innovative, reliable, patient-centric clinical research.
To further accelerate this dynamic growth, Kayentis is proud to welcome Amy Jones as Chief Commercial Officer (CCO). A dual American-French national, Amy brings over 25 years of experience in commercial strategy, business development, and global operations across the clinical research and healthcare sectors, including 20 years at various Top 5 CROs and several years within large- and medium-sized Pharma. Her leadership will be instrumental in deepening relationships with key stakeholders and expanding Kayentis’ footprint in the US and globally.
Recent milestones and expansion highlights:
- New contracts & Preferred Provider status:
Kayentis has secured several major contracts with Top Pharma companies in the past year and is now the preferred provider for four of the world’s Top 15 pharmaceutical companies. These achievements underscore Kayentis’ reputation for reliability and innovation in eCOA and DCT solutions, confirmed by its client recommendation rate, which consistently exceeds 90% over the last 4 years. - Therapeutic area expansion:
With extensive clinical trials experience in over 200 indications and more than 20 therapeutic areas, Kayentis continues to broaden its expertise and supports sponsors and CROs in increasingly complex clinical trials programs. Significant growth has been seen recently in immunology, rare diseases, and oncology clinical research, and Kayentis is able to manage trial complexities across therapeutic areas and populations and to adapt to specificities as needed. - Early-stage study leadership:
Kayentis has seen a marked increase in early-phase (Phase I/II) clinical studies and is proud to be the preferred provider for early-stage oncology studies with a leading Top Pharma partner. This leadership in early development phases confirms the flexibility and agility of the Kayentis’ Clin’form solution and demonstrates Kayentis’ ability to support clients from first-in-human trials through to late-stage development.
Leadership Perspective:
“This exceptional growth in the US market, particularly with our Top Pharma partners, marks a pivotal moment for Kayentis. The appointment of Amy Jones as CCO will further strengthen our ability to deliver value and support our clients’ innovation worldwide,” said Guillaume JUGE, CEO of Kayentis.
“I am thrilled to join Kayentis at such an exciting time and look forward to working with our talented teams and partners to drive continued growth and excellence in patient-centric clinical research,” said Amy Jones.
This announcement follows a series of strategic initiatives to better support pharma, biotech companies, and CROs in defining and implementing eCOA strategies, including the reinforcement of its scientific expertise and the expansion of its eCOA strategy services through the creation of the Kayentis Scientific Advisory Board, and the launch of its Patient Education Video Library to strengthen patient engagement.
About Kayentis
Kayentis, a global leader in eCOA and decentralized clinical trial solutions, empowers pharma, biotech and CROs to streamline data collection in clinical trials, enhancing simplicity, efficiency and data quality. Since 2005, Kayentis has spearheaded clinical development, specializing in eCOA solutions across phases I-IV in over 200 indications across more than 20 therapeutic areas. Adapting to the changing landscape, Kayentis is now offering a comprehensive suite of services to support science-driven and patient-centric clinical research, with operational capabilities across the US, Europe and Asia.
Contact
communication@kayentis.com
